<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210883</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00016754</org_study_id>
    <nct_id>NCT03210883</nct_id>
  </id_info>
  <brief_title>Global Electrical Heterogeneity and Clinical Outcomes</brief_title>
  <acronym>GEHCO</acronym>
  <official_title>Global Electrical Heterogeneity and Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larisa Tereshchenko</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective multicenter cohort will validate an independent association of&#xD;
      electrocardiographic (ECG) global electrical heterogeneity (GEH) measures with sustained&#xD;
      ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients&#xD;
      with primary prevention ICD, and will validate and re-calibrate GEH ECG risk score for&#xD;
      prediction of sustained ventricular tachyarrhythmias and appropriate ICD therapies in&#xD;
      systolic heart failure patients with primary prevention ICD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">July 5, 2021</completion_date>
  <primary_completion_date type="Actual">July 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome: sustained VT/VF event with appropriate ICD therapy (either ATP or shock)</measure>
    <time_frame>up to 15 years</time_frame>
    <description>Sustained ventricular tachyarrhythmia event with appropriate ICD therapy (either antitachycardia pacing or shock)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary competing outcome: All-cause death without preceding sustained VT/VF with appropriate ICD therapy</measure>
    <time_frame>up to 15 years</time_frame>
    <description>All-cause death without preceding sustained ventricular tachyarrhythmia with appropriate ICD therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sustained monomorphic ventricular tachycardia</measure>
    <time_frame>up to 15 years</time_frame>
    <description>Sustained monomorphic ventricular tachycardia with appropriate ICD therapies (either antitachycardia pacing or ICD shock)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sustained polymorphic ventricular tachycardia / ventricular fibrillation</measure>
    <time_frame>up to 15 years</time_frame>
    <description>sustained polymorphic ventricular tachycardia or ventricular fibrillation with appropriate ICD therapies (either antitachycardia pacing or ICD shock)</description>
  </secondary_outcome>
  <enrollment type="Actual">3471</enrollment>
  <condition>Heart Failure</condition>
  <condition>Implantable Defibrillator User</condition>
  <condition>Ventricular Arrythmia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        retrospective records of systolic heart failure patients with primary prevention&#xD;
        ICDs/CRT-Ds implanted for routine clinical indications&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  records of systolic heart failure patients with primary prevention ICDs/CRT-Ds&#xD;
             implanted for routine clinical indications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  absent baseline pre-implant digital ECG;&#xD;
&#xD;
          -  missing data on clinical predictors and covariates;&#xD;
&#xD;
          -  missing ICD programming data (including number of intervals to detect [NID] or time to&#xD;
             detect, number of detection zones, heart rate for each detection zone, and&#xD;
             anti-tachycardia pacing [ATP] programming);&#xD;
&#xD;
          -  missing outcomes data.&#xD;
&#xD;
          -  records of patients with inherited channelopathies (e.g. long QT syndrome, Brugada&#xD;
             syndrome), inherited cardiomyopathies (e.g. hypertrophic cardiomyopathy,&#xD;
             arrhythmogenic right ventricular cardiomyopathy), and congenital heart disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larisa G Tereshchenko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran Administration Portland Healthcare System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Waks JW, Hamilton C, Das S, Ehdaie A, Minnier J, Narayan S, Niebauer M, Raitt M, Tompkins C, Varma N, Chugh S, Tereshchenko LG. Improving sudden cardiac death risk stratification by evaluating electrocardiographic measures of global electrical heterogeneity and clinical outcomes among patients with implantable cardioverter-defibrillators: rationale and design for a retrospective, multicenter, cohort study. J Interv Card Electrophysiol. 2018 Jun;52(1):77-89. doi: 10.1007/s10840-018-0342-2. Epub 2018 Mar 14.</citation>
    <PMID>29541969</PMID>
  </reference>
  <results_reference>
    <citation>Waks JW, Haq KT, Tompkins C, Rogers AJ, Ehdaie A, Bender A, Minnier J, Dalouk K, Howell S, Peiris A, Raitt M, Narayan SM, Chugh SS, Tereshchenko LG. Competing risks in patients with primary prevention implantable cardioverter-defibrillators: Global Electrical Heterogeneity and Clinical Outcomes study. Heart Rhythm. 2021 Jun;18(6):977-986. doi: 10.1016/j.hrthm.2021.03.006. Epub 2021 Mar 6.</citation>
    <PMID>33684549</PMID>
  </results_reference>
  <results_reference>
    <citation>Haq KT, Javadekar N, Tereshchenko LG. Detection and removal of pacing artifacts prior to automated analysis of 12-lead ECG. Comput Biol Med. 2021 Jun;133:104396. doi: 10.1016/j.compbiomed.2021.104396. Epub 2021 Apr 19.</citation>
    <PMID>33872969</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Larisa Tereshchenko</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

